Patients underwent local germline BRCA1/2 testing, whilst tumour testing was performed using the myChoice® companion diagnostic (CDx; Myriad Genetics, Inc., Salt Lake City, UT, USA). This evidence concerns the gene BRCA1 and neoplasm.